PCM
TEVA icon

Penserra Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Penserra Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,444
Closed -$103K – 1184
2026
Q1 		$103K Buy
+3,444
New +$111K ﹤0.01% 730
2025
Q2 		– Sell
-11,584
Closed -$178K – 1130
2025
Q1 		$178K Sell
11,584
-40,059
-78% -$716K ﹤0.01% 752
2024
Q4 		$1.14M Buy
51,643
+42,152
+444% +$767K 0.02% 375
2024
Q3 		$171K Sell
9,491
-151,859
-94% -$2.66M ﹤0.01% 726
2024
Q2 		$2.62M Buy
161,350
+7,620
+5% +$117K 0.03% 320
2024
Q1 		$2.17M Buy
+153,730
New +$1.94M 0.03% 340
2018
Q4 		– Sell
-11,316
Closed -$243K – 777
2018
Q3 		$243K Buy
11,316
+1,599
+16% +$37.1K 0.01% 393
2018
Q2 		$236K Buy
9,717
+673
+7% +$13.7K 0.01% 299
2018
Q1 		$154K Buy
9,044
+714
+9% +$13.9K 0.01% 271
2017
Q4 		$157K Buy
8,330
+1,309
+19% +$19.7K 0.02% 235
2017
Q3 		$129K Buy
+7,021
New +$158K 0.03% 238

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Penserra Capital Management's TEVA Position: Q2 2026 in Review

Penserra Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 3,444 shares — an estimated $103K sold.

Penserra Capital Management first reported a position in TEVA in Q3 2017 and held it in 11 quarters. The position peaked at $2.62M in Q2 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Penserra Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Penserra Capital Management sold 3,444 Teva Pharmaceuticals shares in Q2 2026, an estimated $103K.
  • Penserra Capital Management first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 11 quarters.
  • Penserra Capital Management's Teva Pharmaceuticals position peaked at $2.62M in Q2 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.